Abstract
Human epithelial ovarian carcinoma is well-known as a sex steroid-dependent neoplasm, but the possible biological significance of progesterone receptor (PR) in this cancer remains controversial. Recently, two isoforms of human PR, PRA and PRB, have been characterized and different functional characteristics have been reported for these two isoforms. We therefore examined immunohistochemistry (107 cases) and reverse transcription-polymerase chain reaction (RT-PCR) (16 cases) for PRA, PRB, and oestrogen receptor-a (ER-a). Labeling indices (LI) for PRA and PRB were 2.4 and 43.6, respectively, and the difference was statistically significant. PRB LI, but not PRA LI, as well as performance status, stage, and residual tumour turned out to be independent prognostic factors following multivariate analysis. There was also a significant correlation between ER-a LI and PRB LI (r = 0.595, P < 0.0001), suggestive of a possible interaction between these two receptors. RT-PCR also detected the expression of PR isoform transcripts in the same pattern as was observed with immunohistochemistry. Results of these studies indicate that PRA and PRB both mediate distinct pathways of progesterone action in ovarian carcinoma. Moreover, it is important to examine PRB LI as a prognostic factor in the cases of human epithelial ovarian carcinoma. © 2000 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Ahlgren JD, Ellison NM, Gottlieb RJ, Laluna F, Lokich JJ, Sinclair PR, Ueno W, Wampler GL, Yeung KY, Alt D and Fryer JG (1993 Hormonal palliation of chemoresistant ovarian cancer: three consecutive Phase II trials of the Mid-Atlantic Oncology Program. J Clin Oncol 11: 1957–1968
Benraad THJ, Friberg CG, Koenders AJM and Kullander S (1980 Do estrogen and progesterone receptors (ER and PR) in metastasizing endometrial cancer predict response to estrogen therapy. Acta Obstet Gynecol Scand 59: 155–159
Bizzi A, Codegoni AM and Landoni F (1988 Steroid receptors in epithelial ovarian cancer: Relation to clinical parameters and survival. Cancer Res 48: 6222–6226
Bloom ND, Tobin EH, Schreiberman B and Degenshein GA (1980 The role of progesterone receptors in the treatment of breast cancer. Cancer Res 45: 2992–2997
Clarke CL and Sutherland RL (1990 Progestin regulation of cellular proliferation. Endocr Rev 11: 266–301
Clarke CL, Zaino PD, Feil PD, Miller JV, Steck ME, Ohlsson-Wilhelm BM and Satyaswaroop PG (1987 Monoclonal antibodies to human progesterone receptor: Characterization by biochemical and immunohistochemical techniques. Endocrinology 121: 1123–1132
Critchley HOD, Wang H, Kelly RW, Gebbie AE and Glasier AF (1998 Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of women using a levonorgestrel-releasing intrauterine system. Hum Reprod 13: 1210–1217
Del Campo JM, Felip E, Rubio D, Vidal R, Bermejo B, Colomer R and Zanon V (1994 Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment. Gynecol Oncol 53: 27–32
Ehrlich CE, Young PLM and Cleary RE (1981 Cytoplasmic progesterone and estradiol receptors in normal, hyperplastic and carcinomatous endometria: Therapeutic implications. Am J Obstet Gynecol 141: 539–546
Erhardt K, Aver G, Bjorkholm E, Forsslund G, Moberger B, Silfversward C, Wicksell G and Zetterberg A (1984 Prognostic significance of DNA content in serous ovarian tumors. Cancer Res 44: 2198–2202
Evans RM (1988 The steroid and thyroid hormone receptor superfamily. Science 240: 889–895
Friedlander M, Quinn MA, Fontune D, Foo MS, Toppila M, Hudson CN and Russell P (1989 The relationship of steroid receptor expression to nuclear DNA distribution and clinicopathologic characteristics in epithelial ovarian tumors. Gynecol Oncol 32: 184–190
Fujimoto J, Ichigo S, Hori M, Nishigaki M and Tamaya T (1995 Expression of progesterone receptor form A and B mRNAs in gynecologic malignant tumors. Tumor Biol 16: 254–260
Fujimoto J, Hirose R, Ichigo S, Sakaguchi H, Li Y and Tamaya T (1998 Expression of progesterone receptor form A and B mRNAs in uterine leiomyoma. Tumor Biol 19: 126–131
Geisler JP, Wiemann MC, Miller GA and Geisler HE (1996 Estrogen and progesterone receptor status as prognostic indicators in patients with optimally cytoreduced stage IIIc serous cystadenocarcinoma of the ovary. Gynecol Oncol 60: 424–427
Giangrande PH, Pollio G and McDonnell DP (1997 Mapping and characterization of the functional domains responsible for the differential activity of the A and B isoforms of the human progesterone receptor. J Biol Chem 272: 32889–32900
Graham JD, Roman SD, McGowan EM, Sutherland RL and Clarke CL (1995 Preferential stimulation of human progesterone receptor B expression by estrogen in T47D human breast cancer cell lines. J Biol Chem 270: 30693–30700
Graham JD, Yeates C, Balleine RL, Harvey SS, Milliken JS, Bilous AM and Clarke CL (1996 Progesterone receptor A and B protein expression in human breast cancer. J Steroid Biochem Mol Biol 56: 93–98
Heintz APM, Hacker NF, Berek JS, Rose TP, Munoz AK and Lagasse LD (1986 Cytoreductive surgery in ovarian carcinoma: Feasibility and morbidity. Obstet Gynecol 67: 783–788
Hempling RE, Piver MS, Eltabbakh GH and Recio FO (1998 Progesterone receptor status is a significant prognostic variable of progression-free survival in advanced epithelial ovarian cancer. Am J Clin Oncol 21: 447–451
Hirasawa G, Sasano H, Takahashi K, Fukushima K, Suzuki T, Hiwatashi N, Toyota T, Krozowski ZS and Nagura H (1997 Colocalization of 11β-hydroxysteroid dehydrogenase type II and mineralcorticoid receptor in human epithelia. J Clin Endoclinol Metab 82: 3859–3863
Horwitz KB (1981 Is a functional estrogen receptor always required for progesterone receptor induction in breast cancer?. J Steroid Biochem 15: 209–217
Horwitz KB and Alexander PS (1983 In situ photolinked nuclear progesterone receptors of human breast cancer cell lines: subunit molecular weights after transformation and translocation. Endocrinology 113: 2195–2201
International Federation of Gynecology and Obstetrics (1987 Changes in definitions of clinical staging for adenocarcinoma of the cervix and ovary. Am J Obstet Gynecol 156: 263–264
Inversen OE, Skaarland E and Utaaker E (1986 Steroid receptor content in human ovarian tumors: Survival of patients with ovarian carcinoma related to steroid receptor content. Gynecol Oncol 23: 65–76
Jeltsch JM, Krozowski Z, Qurin-Stricker C, Gronemeyer H, Simpson RJ, Garnier JM, Krust A, Jacob F and Chambon P (1986 Cloning of the chicken progesterone receptor. Proc Natl Acad Sci USA 83: 5424–5428
Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer H and Chambon P (1990 Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J 9: 1603–1614
Katzenellenbogen BS and Norman MJ (1990 Multihormonal regulation of the progesterone receptor in MCF-7 human breast cancer cells: Interrelationships among insulin/insulin-like growth factor-1, serum, and estrogen. Endocrinology 126: 891–898
Kaupilla A (1984 Progestin therapy of endometrial, breast and ovarian carcinoma: A review of clinical observations. Acta Obstet Gynecol Scand 63: 441–450
Kommoss F, Pfisterer J, Thome M, Schafer W, Sauerbrei W and Pfleiderer A (1992 Steroid receptors in ovarian carcinoma: Immunohistochemical determination may lead to new aspects. Gynecol Oncol 47: 317–322
Kraus WL, Weis KE and Katzenellenbogen BS (1995 Inhibitory cross-talk between steroid hormone receptors: differential targeting of estrogen receptor in the repression of its transcriptional activity by agonist- and antagonist-occupied progestin receptors. Mol Cell Biol 15: 1847–1857
Kumar NS, Richer J, Owen G, Litman E, Horwitz KB and Leslie KK (1998 Selective down-regulation of progesterone receptor isoforms B in poorly differentiated human endometrial cancer cells: Implications for unopposed estrogen action. Cancer Res 58: 1860–1865
Langdon SP, Gabra H, Bartlett JMS, Rabiaz GJ, Hawkins RA f Tesdale AL, Ritchie AA, Miller WR and Smyth JF (1998 Functionality of the progesterone receptor in ovarian cancer and its regulation by estrogen. Clin Cancer Res 4: 2245–2251
Mangal RK, Wiehle RD, Poindexter AN and Weigel NL (1997 Differential expression of uterine progesterone receptor forms A and B during the menstrual cycle. J Steroid Biochem Molec Biol 63: 195–202
Masood S, Heitmann J, Nuss RC and Benrubi GI (1989 Clinical correlation of hormone receptor status in epithelial ovarian cancer. Gynecol Oncol 34: 57–60
McGuire WL (1978 Steroid receptors in human breast cancer. Cancer Res 38: 4289–4291
Mote PA, Balleine RL, McGowan EM and Clarke CL (1999 Colocalization of progesterone receptors A and B by dual immunofluorescent histochemistry in human endometrium during the menstrual cycle. J Clin Endocrinol Metabol 84: 2963–2971
Nakashima N, Nagasaka T, Fukata S, Oiwa N, Nara Y, Fukatsu T and Takeuchi J (1990 Study of ovarian tumors treated at Nagoya University Hospital, 1965–1988. Gynecol Oncol 37: 103–111
Omura GA, Brady MF, Homesley HD, Yordan E, Major FJ, Buchsbaum HJ and Park RC (1991 Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: The gynecologic oncology group experience. J Clin Oncol 9: 1138–1150
Osborne CK, Yochmowitz MG, Knight WA and McGuire WL (1980 The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46: 2884–2888
Pettersson F (1994 Annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 22: 83–102
Piver MS, Lele SB, Marchetti DL, Baker TR, Tsukada Y and Emrich LJ (1988 The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma. J Clin Oncol 6: 983–989
Rao BR and Slotman BJ (1991 Endocrine factors in common epithelial ovarian cancer. Endocrine Rev 12: 14–26
Redman JR, Petrini GR, Saigo PE, Geller NL and Hakes TB (1986 Prognostic factors in advanced ovarian carcinoma. J Clin Oncol 4: 515–523
Sambrook J, Fritsch EF and Maniatis T (year?). Molecular cloning, a laboratory manual, Extraction, purification and analysis of messenger RNA from eukaryotic cells vol 1, pp 7.1–7.87, Spring Harbor Laboratory Press: Plainview, New York
Sasano H, Frost AR, Saitoh R, Harada N, Poutanen M, Vihko R, Bulin SE, Silverberg SG and Nagura H (1996 Aromatase and 17 β-hydroxysteroid dehydrogenase type 1 in human breast carcinoma. J Clin Endoclinol Metab 81: 4042–4046
Savouret JF, Misrahi M and Milgrom E (1990 Molecular action of progesterone. Int J Biochem 22: 579–594
Sevelda P, Denison U, Schemper M, Spona J, Vavra N and Salzer H (1990 Oestrogen and progesterone receptor content as a prognostic factor in advanced epithelial ovarian carcinoma. Br J Obstet Gynecol 97: 706–712
Shughrue PJ, Lubahn DB, Negro-Vilar A, Korach KS and Merchenthaler I (1997 Responses in the brain of estrogen receptor α-disrupted mice. Proc Natl Acad Sci USA 94: 11008–11012
Simpson BJB, Langdon SP, Rabiasz GJ, Macleod KG, Hirst GL, Bartlett JMS, Crew AJ, Hawkins RA, Macineira-Perez PP, Smyth JF and Miller WR (1998 Estrogen regulation of transforming growth factor-α in ovarian cancer. J Steroid Biochem Mol Biol 64: 137–145
Slotman BJ, Kuhnel R, Rao BR, Dijkhuizen GH, deGraaf J and Stolk JG (1989 Importance of steroid receptors and aromatase activity in the prognosis of ovarian cancer: High tumor progesterone receptor levels correlate with longer survival. Gynecol Oncol 33: 76–81
Syvala H, Vienonen A, Ylikomi T, Blauer M, Zhuang YH and Tuohimaa P (1997 Expression of the chick progesterone receptor forms A and B is differentially regulated by estrogen in vivo. Biochem Biophys Res Commun 231: 573–576
Vegeto E, Shahbaz MM, Wen DX, Goldman ME, O’Malley BW and McDonell DP (1993 Human progesterone receptor A form is a cell- and promoter-specific repress or of human progesterone receptor B function. Mol Endocrinol 7: 1244–1255
Viville B, Charnock-Jones DS, Sharkey AM, Wetzka B and Smith SK (1997 Distribution of the A and B forms of the progesterone receptor messenger ribonucleic acid and protein in uterine leiomyomata and adjacent myometrium. Hum Reprod 12: 815–822
Volm M, Bruggeman A, Gunther M, Kleine W, Pfleiderer A and Vogt-Schaden M (1985 Prognostic significance of ploidy and proliferation in ovarian carcinoma. Cancer Res 45: 5180–5185
Wang H, Critchley HOD, Kelly RW, Shen D and Baird DT (1998 Progesterone receptor subtype B is differentially regulated in human endometrial stroma. Mol Hum Reprod 4: 407–412
Wen DX, Xu YF, Mais DE, Godman ME and McDonnell DP (1994 The A and B isoform of the human progesterone receptor operate through distinct signaling pathways within target cells. Mol Cell Biol 14: 8356–8364
World Health Organization (1979). Handbook for reporting results of cancer treatment. WHO publication no. 48, World Health Organization: Geneva
Young RC, Chabner BA, Hubbard SP, Fischer RI, Bender RA, Anderson T, Simon RM, Canellos GP and De Vita VT (1978 Advanced ovarian adenocarcinoma: A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. New Engl J Med 299: 1261–1266
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Akahira, J., Inoue, T., Suzuki, T. et al. Progesterone receptor isoforms A and B in human epithelial ovarian carcinoma: immunohistochemical and RT-PCR studies. Br J Cancer 83, 1488–1494 (2000). https://doi.org/10.1054/bjoc.2000.1463
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1463
Keywords
This article is cited by
-
Estrogen receptor β is associated with expression of cancer associated genes and survival in ovarian cancer
BMC Cancer (2018)
-
Steroid hormone receptor expression in ovarian cancer: progesterone receptor B as prognostic marker for patient survival
BMC Cancer (2012)
-
Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the ovarian cancer association consortium pooled analysis
British Journal of Cancer (2008)
-
Estrogen-induced loss of progesterone receptor expression in normal and malignant ovarian surface epithelial cells
Oncogene (2005)
-
Possible effects of progesterone on human central nervous system and neurogenic tumors
Journal of Endocrinological Investigation (2004)